Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Bonello

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Cancers|November 8, 2019
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled AnalysisFrancesca Bonello, Stefano Pulini, Stelvio Ballanti, et al.
Haematologica|November 20, 2023
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agentsRoberto Mina, Maria Teresa Petrucci, Francesca Bonello, et al.
British Journal of Haematology|June 11, 2025
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, et al.
Blood Cancer Journal|April 13, 2021
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty scoreMattia D'Agostino, Alessandra Larocca, Massimo Offidani, et al.
Blood Cancer Journal|December 8, 2021
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trialRoberto Mina, Antonietta Pia Falcone, Sara Bringhen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY ProjectMattia D'Agostino, David A Cairns, Juan José Lahuerta, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Cancers|November 8, 2019
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled AnalysisFrancesca Bonello, Stefano Pulini, Stelvio Ballanti, et al.
Haematologica|November 20, 2023
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agentsRoberto Mina, Maria Teresa Petrucci, Francesca Bonello, et al.
British Journal of Haematology|June 11, 2025
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, et al.
Blood Cancer Journal|April 13, 2021
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty scoreMattia D'Agostino, Alessandra Larocca, Massimo Offidani, et al.
Blood Cancer Journal|December 8, 2021
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trialRoberto Mina, Antonietta Pia Falcone, Sara Bringhen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY ProjectMattia D'Agostino, David A Cairns, Juan José Lahuerta, et al.
Pageof 3